Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
Mohamed Abo-Aly, Neurology Resident at Montefiore Medical Center – Albert Einstein College of Medicine, Transitional Year Resident at Saint Agnes Medical Center, shared a post on X about a recent article by Kai Michael Schubert et al., published in JAMA Neurology, adding:
“Which antiseizure medication (ASM) is safest for patients on DOACs?
A new target trial emulation published in JAMA Neurology (Schubert et al.) analyzes 9,500+ adults with epilepsy on DOACs to evaluate risks of thromboembolism, bleeding, and mortality.
The authors tested the assumption that keppra is interaction-free using Trinetx dataset comparing monotherapt regimens to neutral reference: lamotrigine or lacosamide. Cohorts were 1:1 propensity score matched.
Levetiracetam (Keppra):
Relative to lamotrigine or lacosamide, levetiracetam was associated with:
- High Thromboembolic risk: HR 1.98 (95% CI, 1.37–2.87)
- High All-cause mortality: HR 1.60 (95% CI, 1.23–2.08)
- Major bleeding: No significant difference (HR 0.99)
Strong Enzyme-Inducers and Valproate:
Strong inducers (phenytoin, carbamazepine): Higher thromboembolic risk (HR 1.55) alongside lower bleeding risk (HR 0.62)—consistent with reduced DOAC exposure.
Valproate: Higher mortality (HR 1.49) and a 3-fold higher risk of major intracranial bleeding (HR 3.01)
The VKA Reality Check (Negative Control): Crucially, among patients treated with VKAs (warfarin) instead of DOACs, thromboembolic hazard ratios across all ASM groups were near null.
Counterfactual modeling showed that switching eligible patients to lamotrigine or lacosamide could theoretically prevent approximately 28% of all thromboembolic events in this population.
Practice Implications:
ASM choice is a modifiable risk factor in anticoagulated patients: Avoid assuming levetiracetam is completely interaction-neutral with DOACs.”
Title: Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy
Authors: Kai Michael Schubert, Carolina Ferreira-Atuesta, Arunachalam Soma, Johan Zelano, David J. Seiffge, Francesco Brigo, Eugen Trinka, Nishant K. Mishra, Emilio Russo, Gregory Y. H. Lip, Gashirai K Mbizvo, Marian Galovic
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week